VVT Med Inc.

As of June 30, 2026, VVT Med Inc. carries a market capitalization of 16.68M, placing it among publicly traded companies globally. Its enterprise value stands at 18.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, VVT Med Inc. has 72.59M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 114.54, and the price-to-book ratio stands at -6.43.

These figures are as of June 30, 2026. The EV/Sales ratio of 134.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 18.32M versus a market cap of 16.68M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, VVT Med Inc. maintains a current ratio of 0.16, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -63.70, indicating conservative leverage, while an interest coverage ratio of -25.57 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -382.85, reflecting losses generated across the asset base. Inventory turnover of 0.13 indicates how many times VVT Med Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, VVT Med Inc.'s stock has declined approximately 39.06% over the past 52 weeks. The 50-day moving average sits at 0.22, while the 200-day moving average is 0.28.

Over the twelve months ended June 30, 2026, VVT Med Inc. generated 136,244.16 in revenue and converted that into -5.83M in net income, yielding earnings per share of -0.09. EBITDA reached -7.40M, while operating income came in at -7.62M.

As of June 30, 2026, VVT Med Inc. holds 12,772.89 in cash and equivalents against 1.65M in total debt, resulting in a net debt position of 949,451.49. Total book value stands at -2.60M, with working capital of -2.86M providing operational flexibility.

VVT Med Inc. produced -4.66M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -7,096.05 in capital expenditures, free cash flow totaled -4.67M - equivalent to -0.07 per share.

Over the twelve months ended June 30, 2026, VVT Med Inc. posted a gross margin of 63.54, reflecting its pricing power and cost economics. The operating margin of -5,592.71 and net profit margin of -4,279.17 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -29.91: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -24.52, meaning VVT Med Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

VVT Med Inc.'s most recent stock split took place on July 31, 2025 with a 467:100 split ratio.

As of June 30, 2026, VVT Med Inc. has an Altman Z-Score of -65.02, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.